Pretargeted radioimmunotherapy with α-particle emitting radionuclides

Current Radiopharmaceuticals

Volumn 4, Issue 3, 2011, Pages 248-260

  Lindegren, Sture ^a   Frost, Sofia H L ^a  

^a SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Pretargeted; Pretargeting; Radioimmunotherapy; particle

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ASTATINE 211; AVIDIN; BIOTIN; BISMUTH 213; BISPECIFIC ANTIBODY; CD20 ANTIBODY; COMPLEMENTARY DNA; IBRITUMOMAB TIUXETAN; INDIUM 111; IODINE 131; MONOCLONAL ANTIBODY; MORPHOLINE DERIVATIVE; TOSITUMOMAB; TOSITUMOMAB I 131; YTTRIUM 90;

ALPHA RADIATION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; DISSEMINATED CANCER; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; ISOTOPE LABELING; LINEAR ENERGY TRANSFER; METASTASIS; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; TUMOR LOCALIZATION;

EID: 79959426898     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471011104030248     Document Type: Review

References (113)

1. Kohler, G.; Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 1975, 256 (5517), 495-497.
2. Karagiannis, T. C. Radioimmunotherapy: Principles, current trends and future directions, Hell. J. Nucl. Med., 2004, 7 (1), 39-43.
3. Elgqvist, J.; Andersson, H.; Jensen, H.; Kahu, H.; Lindegren, S.; Warnhammar, E.; Hultborn, R. Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice, J. Oncol., 2010, 2010, 394913.
4. Jacene, H. A.; Filice, R.; Kasecamp, W.; Wahl, R. L. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice, J. Nucl. Med., 2007, 48 (11), 1767-1776.
5. Milenic, D. E.; Wong, K. J.; Baidoo, K. E.; Ray, G. L.; Garmestani, K.; Williams, M.; Brechbiel, M. W. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications, Cancer Biother. Radiopharm., 2008, 23 (5), 619-631.
6. Wang, W.; Wang, E. Q.; Balthasar, J. P. Monoclonal antibody pharmacokinetics and pharmacodynamics, Clin. Pharmacol. Ther., 2008, 84 (5), 548-558.
7. Tabrizi, M.; Bornstein, G. G.; Suria, H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease, AAPS J, 2010, 12 (1), 33-43.
8. Behr, T. M.; Behe, M.; Sgouros, G. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings, Cancer Biother. Radiopharm., 2002, 17 (4), 445-464.
9. Kaminski, M. S.; Estes, J.; Zasadny, K. R.; Francis, I. R.; Ross, C. W.; Tuck, M.; Regan, D.; Fisher, S.; Gutierrez, J.; Kroll, S.; Stagg, R.; Tidmarsh, G.; Wahl, R. L. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience, Blood, 2000, 96 (4), 1259-1266.
10. Gordon, L. I.; Witzig, T. E.; Wiseman, G. A.; Flinn, I. W.; Spies, S. S.; Silverman, D. H.; Emmanouilides, C.; Cripe, L.; Saleh, M.; Czuczman, M. S.; Olejnik, T.; White, C. A.; Grillo-Lopez, A. J. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma, Semin. Oncol., 2002, 29 (1 Suppl 2), 87-92.
11. Andersson, H.; Cederkrantz, E.; Back, T.; Divgi, C.; Elgqvist, J.; Himmelman, J.; Horvath, G.; Jacobsson, L.; Jensen, H.; Lindegren, S.; Palm, S.; Hultborn, R. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study, J. Nucl. Med., 2009, 50 (7), 1153-1160.
12. Zalutsky, M. R.; Reardon, D. A.; Akabani, G.; Coleman, R. E.; Friedman, A. H.; Friedman, H. S.; McLendon, R. E.; Wong, T. Z.; Bigner, D. D. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211Atlabeled chimeric antitenascin monoclonal antibody 81C6, J. Nucl. Med., 2008, 49 (1), 30-38.
13. Colcher, D.; Pavlinkova, G.; Beresford, G.; Booth, B. J.; Choudhury, A.; Batra, S. K. Pharmacokinetics and biodistribution of genetically-engineered antibodies, Q. J. Nucl. Med., 1998, 42 (4), 225-241.
14. Sharkey, R. M.; Karacay, H.; Johnson, C. R.; Litwin, S.; Rossi, E. A.; McBride, W. J.; Chang, C. H.; Goldenberg, D. M. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma, J. Nucl. Med., 2009, 50 (3), 444-453.
15. Park, S. I.; Shenoi, J.; Pagel, J. M.; Hamlin, D. K.; Wilbur, D. S.; Orgun, N.; Kenoyer, A. L.; Frayo, S.; Axtman, A.; Back, T.; Lin, Y.; Fisher, D. R.; Gopal, A. K.; Green, D. J.; Press, O. W. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease, Blood, 2010, 116 (20), 4231-4239.
16. Palanca-Wessels, M. C.; Press, O. W. Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas, Cancer, 2010, 116 (4 Suppl), 1126-1133.
17. Goodwin, D. A.; Meares, C. F.; David, G. F.; McTigue, M.; McCall, M. J.; Frincke, J. M.; Stone, M. R.; Bartholomew, R. M.; Leung, J. P. Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals, Int. J. Rad. Appl. Instrum. B., 1986, 13 (4), 383-391.
18. Goodwin, D. A.; Meares, C. F.; McCall, M. J.; McTigue, M.; Chaovapong, W. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens, J. Nucl. Med., 1988, 29 (2), 226-234.
19. Boerman, O. C.; van Schaijk, F. G.; Oyen, W. J.; Corstens, F. H. Pretargeted radioimmunotherapy of cancer: progress step by step, J. Nucl. Med., 2003, 44 (3), 400-411.
20. Goldenberg, D. M.; Sharkey, R. M.; Paganelli, G.; Barbet, J.; Chatal, J. F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy, J. Clin. Oncol., 2006, 24 (5), 823-834.
21. Goldenberg, D. M.; Chatal, J. F.; Barbet, J.; Boerman, O.; Sharkey, R. M. Cancer Imaging and Therapy with Bispecific Antibody Pretargeting, Update Cancer Ther, 2007, 2 (1), 19-31.
22. Liu, G.; Hnatowich, D. J. A semiempirical model of tumor pretargeting, Bioconjug. Chem., 2008, 19 (11), 2095-2104.
23. Lesch, H. P.; Kaikkonen, M. U.; Pikkarainen, J. T.; Yla-Herttuala, S. Avidin-biotin technology in targeted therapy, Expert Opin. Drug Deliv, 2010, 7 (5), 551-564.
24. Goodwin, D. A.; Meares, C. F. Advances in pretargeting biotechnology, Biotechnol. Adv., 2001, 19 (6), 435-450.
25. Green, N. M. Avidin, Adv. Protein Chem., 1975, 29, 85-133.
26. Diamandis, E. P.; Christopoulos, T. K. The biotin-(strept)avidin system: principles and applications in biotechnology, Clin. Chem., 1991, 37 (5), 625-636.
27. Hnatowich, D. J.; Virzi, F.; Rusckowski, M. Investigations of avidin and biotin for imaging applications, J. Nucl. Med., 1987, 28 (8), 1294-1302.
28. Kalofonos, H. P.; Rusckowski, M.; Siebecker, D. A.; Sivolapenko, G. B.; Snook, D.; Lavender, J. P.; Epenetos, A. A.; Hnatowich, D. J. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication, J. Nucl. Med., 1990, 31 (11), 1791-1796.
29. Goodwin, D.; Meares, C.; Diamanti, C.; McCall, M.; Lai, C.; Torti, F.; McTigue, M.; Martin, B. Use of specific antibody for rapid clearance of circulating blood background from radiolabeled tumor imaging proteins, Eur. J. Nucl. Med., 1984, 9 (5), 209-215.
30. Paganelli, G.; Belloni, C.; Magnani, P.; Zito, F.; Pasini, A.; Sassi, I.; Meroni, M.; Mariani, M.; Vignali, M.; Siccardi, A. G.; et al. Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin, Eur. J. Nucl. Med., 1992, 19 (5), 322-329.
31. Colombo, P.; Siccardi, A. G.; Paganelli, G.; Magnani, P.; Songini, C.; Buffa, R.; Faglia, G.; Fazio, F. Three-step immunoscintigraphy with anti-chromogranin A monoclonal antibody in tumours of the pituitary region, Eur. J. Endocrinol., 1996, 135 (2), 216-221.
32. Paganelli, G.; Magnani, P.; Zito, F.; Villa, E.; Sudati, F.; Lopalco, L.; Rossetti, C.; Malcovati, M.; Chiolerio, F.; Seccamani, E.; et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients, Cancer Res., 1991, 51 (21), 5960-5966.
33. Schechter, B.; Silberman, R.; Arnon, R.; Wilchek, M. Tissue distribution of avidin and streptavidin injected to mice. Effect of avidin carbohydrate, streptavidin truncation and exogenous biotin, Eur. J. Biochem., 1990, 189 (2), 327-331.
34. Magnani, P.; Fazio, F.; Grana, C.; Songini, C.; Frigerio, L.; Pecorelli, S.; Mangili, G.; Colombo, N.; Mariani, C. D.; Paganelli, G. Diagnosis of persistent ovarian carcinoma with three-step immunoscintigraphy, Br. J. Cancer, 2000, 82 (3), 616-620.
35. Grana, C.; Chinol, M.; Robertson, C.; Mazzetta, C.; Bartolomei, M.; De Cicco, C.; Fiorenza, M.; Gatti, M.; Caliceti, P.; Paganelli, G. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study, Br. J. Cancer, 2002, 86 (2), 207-212.
36. Weiden, P. L.; Breitz, H. B. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL), Crit. Rev. Oncol. Hematol., 2001, 40 (1), 37-51.
37. Goldrosen, M. H.; Biddle, W. C.; Pancook, J.; Bakshi, S.; Vanderheyden, J. L.; Fritzberg, A. R.; Morgan, A. C., Jr.; Foon, K. A. Biodistribution, pharmacokinetic, and imaging studies with 186Re-labeled NR-LU-10 whole antibody in LS174T colonic tumor-bearing mice, Cancer Res., 1990, 50 (24), 7973-7978.
38. Breitz, H. B.; Weiden, P. L.; Beaumier, P. L.; Axworthy, D. B.; Seiler, C.; Su, F. M.; Graves, S.; Bryan, K.; Reno, J. M. Clinical optimization of pretargeted radioimmunotherapy with antibodystreptavidin conjugate and 90Y-DOTA-biotin, J. Nucl. Med., 2000, 41 (1), 131-140.
39. Knox, S. J.; Goris, M. L.; Tempero, M.; Weiden, P. L.; Gentner, L.; Breitz, H.; Adams, G. P.; Axworthy, D.; Gaffigan, S.; Bryan, K.; Fisher, D. R.; Colcher, D.; Horak, I. D.; Weiner, L. M. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer, Clin. Cancer Res., 2000, 6 (2), 406-414.
40. Breitz, H. B.; Fisher, D. R.; Goris, M. L.; Knox, S.; Ratliff, B.; Murtha, A. D.; Weiden, P. L. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin, Cancer Biother Radiopharm, 1999, 14 (5), 381-395.
41. Press, O. W.; Corcoran, M.; Subbiah, K.; Hamlin, D. K.; Wilbur, D. S.; Johnson, T.; Theodore, L.; Yau, E.; Mallett, R.; Meyer, D. L.; Axworthy, D. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts, Blood, 2001, 98 (8), 2535-2543.
42. Reardan, D. T.; Meares, C. F.; Goodwin, D. A.; McTigue, M.; David, G. S.; Stone, M. R.; Leung, J. P.; Bartholomew, R. M.; Frincke, J. M. Antibodies against metal chelates, Nature, 1985, 316 (6025), 265-268.
43. Stickney, D. R.; Anderson, L. D.; Slater, J. B.; Ahlem, C. N.; Kirk, G. A.; Schweighardt, S. A.; Frincke, J. M. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma, Cancer Res., 1991, 51 (24), 6650-6655.
44. Gridley, D. S.; Ewart, K. L.; Cao, J. D.; Stickney, D. R. Hyperthermia enhances localization of 111In-labeled hapten to bifunctional antibody in human colon tumor xenografts, Cancer Res., 1991, 51 (5), 1515-1520.
45. Le Doussal, J. M.; Martin, M.; Gautherot, E.; Delaage, M.; Barbet, J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate, J. Nucl. Med., 1989, 30 (8), 1358-1366.
46. Barbet, J.; Kraeber-Bodere, F.; Vuillez, J. P.; Gautherot, E.; Rouvier, E.; Chatal, J. F. Pretargeting with the affinity enhancement system for radioimmunotherapy, Cancer Biother Radiopharm, 1999, 14 (3), 153-166.
47. Le Doussal, J. M.; Gautherot, E.; Martin, M.; Barbet, J.; Delaage, M. Enhanced in vivo targeting of an asymmetric bivalent hapten to double-antigen-positive mouse B cells with monoclonal antibody conjugate cocktails, J. Immunol., 1991, 146 (1), 169-175.
48. Gautherot, E.; Rouvier, E.; Daniel, L.; Loucif, E.; Bouhou, J.; Manetti, C.; Martin, M.; Le Doussal, J. M.; Barbet, J. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten, J. Nucl. Med., 2000, 41 (3), 480-487.
49. Goodwin, D. A.; Meares, C. F.; McTigue, M.; Chaovapong, W.; Diamanti, C. I.; Ransone, C. H.; McCall, M. J. Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake, J. Nucl. Med., 1992, 33 (11), 2006-2013.
50. Kraeber-Bodere, F.; Faibre-Chauvet, A.; Sai-Maurel, C.; Gautherot, E.; Fiche, M.; Campion, L.; Le Boterff, J.; Barbet, J.; Chatal, J. F.; Thedrez, P. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft, J. Nucl. Med., 1999, 40 (1), 198-204.
51. Boerman, O. C.; Kranenborg, M. H.; Oosterwijk, E.; Griffiths, G. L.; McBride, W. J.; Oyen, W. J.; de Weijert, M.; Oosterwijk-Wakka, J.; Hansen, H. J.; Corstens, F. H. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate, Cancer Res., 1999, 59 (17), 4400-4405.
52. Janevik-Ivanovska, E.; Gautherot, E.; Hillairet de Boisferon, M.; Cohen, M.; Milhaud, G.; Tartar, A.; Rostene, W.; Barbet, J.; Gruaz-Guyon, A. Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy, Bioconjug. Chem., 1997, 8 (4), 526-533.
53. Sharkey, R. M.; McBride, W. J.; Karacay, H.; Chang, K.; Griffiths, G. L.; Hansen, H. J.; Goldenberg, D. M. A universal pretargeting system for cancer detection and therapy using bispecific antibody, Cancer Res., 2003, 63 (2), 354-363.
54. Filpula, D. Antibody engineering and modification technologies, Biomol Eng, 2007, 24 (2), 201-215.
55. Kontermann, R. E. Recombinant bispecific antibodies for cancer therapy, Acta Pharmacol Sin, 2005, 26 (1), 1-9.
56. Chang, C. H.; Rossi, E. A.; Goldenberg, D. M. The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity, Clin. Cancer Res., 2007, 13 (18 Pt 2), 5586s-5591s.
57. Rossi, E. A.; Goldenberg, D. M.; Cardillo, T. M.; McBride, W. J.; Sharkey, R. M.; Chang, C. H. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, Proc. Natl. Acad. Sci. U. S. A., 2006, 103 (18), 6841-6846.
58. Kuijpers, W. H.; Bos, E. S.; Kaspersen, F. M.; Veeneman, G. H.; van Boeckel, C. A. Specific recognition of antibodyoligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for two-step radioimmunotherapy of cancer, Bioconjug. Chem., 1993, 4 (1), 94-102.
59. Hnatowich, D. J. Pharmacokinetic considerations in the development of oligomers as radiopharmaceuticals, Q. J. Nucl. Med., 1997, 41 (2), 91-100.
60. Rusckowski, M.; Qu, T.; Chang, F.; Hnatowich, D. J. Pretargeting using peptide nucleic acid, Cancer, 1997, 80 (12 Suppl), 2699-2705.
61. Mang'era, K. O.; Liu, G.; Yi, W.; Zhang, Y.; Liu, N.; Gupta, S.; Rusckowski, M.; Hnatowich, D. J. Initial investigations of 99mTclabeled morpholinos for radiopharmaceutical applications, Eur. J. Nucl. Med., 2001, 28 (11), 1682-1689.
62. Liu, G.; Mang'era, K.; Liu, N.; Gupta, S.; Rusckowski, M.; Hnatowich, D. J. Tumor pretargeting in mice using (99m)Tclabeled morpholino, a DNA analog, J. Nucl. Med., 2002, 43 (3), 384-391.
63. He, J.; Liu, G.; Gupta, S.; Zhang, Y.; Rusckowski, M.; Hnatowich, D. J. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept, J. Nucl. Med., 2004, 45 (6), 1087-1095.
64. He, J.; Liu, X.; Zhang, S.; Liu, G.; Hnatowich, D. J. Affinity enhancement bivalent morpholinos for pretargeting: surface plasmon resonance studies of molecular dimensions, Bioconjug. Chem., 2005, 16 (5), 1098-1104.
65. He, J.; Liu, G.; Vanderheyden, J. L.; Dou, S.; Mary, R.; Hnatowich, D. J. Affinity enhancement bivalent morpholino for pretargeting: initial evidence by surface plasmon resonance, Bioconjug Chem, 2005, 16 (2), 338-345.
66. Chmura, A. J.; Orton, M. S.; Meares, C. F. Antibodies with infinite affinity, Proc. Natl. Acad. Sci. U. S. A., 2001, 98 (15), 8480-8484.
67. Chmura, A. J.; Schmidt, B. D.; Corson, D. T.; Traviglia, S. L.; Meares, C. F. Electrophilic chelating agents for irreversible binding of metal chelates to engineered antibodies, J Control Release, 2002, 78 (1-3), 249-258.
68. Corneillie, T. M.; Whetstone, P. A.; Lee, K. C.; Wong, J. P.; Meares, C. F. Converting weak binders into infinite binders, Bioconjug. Chem., 2004, 15 (6), 1389-1391.
69. Wei, L. H.; Olafsen, T.; Radu, C.; Hildebrandt, I. J.; McCoy, M. R.; Phelps, M. E.; Meares, C.; Wu, A. M.; Czernin, J.; Weber, W. A. Engineered antibody fragments with infinite affinity as reporter genes for PET imaging, J. Nucl. Med., 2008, 49 (11), 1828-1835.
70. Humm, J. L. Dosimetric aspects of radiolabeled antibodies for tumor therapy, J. Nucl. Med., 1986, 27 (9), 1490-1497.
71. Wilbur, D. S. Potential Use of Alpha-Emitting Radionuclides in the Treatment of Cancer, Antibody Immunoconjugates and Radiopharmaceuticals, 1991, 4 (1), 85-97.
72. Zalutsky, M. R.; Vaidyanathan, G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy, Curr. Pharm. Des., 2000, 6 (14), 1433-1455.
73. McDevitt, M. R.; Sgouros, G.; Finn, R. D.; Humm, J. L.; Jurcic, J. G.; Larson, S. M.; Scheinberg, D. A. Radioimmunotherapy with alpha-emitting nuclides, Eur. J. Nucl. Med., 1998, 25 (9), 1341-1351.
74. Sgouros, G. Alpha-particles for targeted therapy, Adv Drug Deliv Rev, 2008, 60 (12), 1402-1406.
75. Mulford, D. A.; Scheinberg, D. A.; Jurcic, J. G. The promise of targeted {alpha}-particle therapy, J. Nucl. Med., 2005, 46 Suppl 1, 199S-204S.
76. Tolmachev, V.; Carlsson, J.; Lundqvist, H. A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy--availability of suitable radionuclides, Acta Oncol., 2004, 43 (3), 264-275.
77. Apostolidis, C.; Molinet, R.; Rasmussen, G.; Morgenstern, A. Production of Ac-225 from Th-229 for targeted alpha therapy, Anal. Chem., 2005, 77 (19), 6288-6291.
78. Foulon, C. F.; Alston, K. L.; Zalutsky, M. R. Synthesis and preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide and (5-iodo-3-pyridinyl)carbonyl)norbiotinamide: two radioiodinated biotin conjugates with improved stability, Bioconjug Chem, 1997, 8 (2), 179-186.
79. Foulon, C. F.; Adelstein, S. J.; Kassis, A. I. One-step synthesis of radioiodinated biotin derivatives, Bioorg. Med. Chem. Lett., 1996, 6 (7), 779-784.
80. Hymes, J.; Wolf, B. Biotinidase and its roles in biotin metabolism, Clin. Chim. Acta, 1996, 255 (1), 1-11.
81. Larsen, R. H.; Slade, S.; Zalutsky, M. R. Blocking [211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds, Nucl. Med. Biol., 1998, 25 (4), 351-357.
82. Foulon, C. F.; Alston, K. L.; Zalutsky, M. R. Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy, Nucl. Med. Biol., 1998, 25 (2), 81-88.
83. Wilbur, D. S.; Pathare, P. M.; Hamlin, D. K.; Weerawarna, S. A. Biotin reagents for antibody pretargeting. 2. Synthesis and in vitro evaluation of biotin dimers and trimers for cross-linking of streptavidin, Bioconjug. Chem., 1997, 8 (6), 819-832.
84. Wilbur, D. S.; Pathare, P. M.; Hamlin, D. K.; Buhler, K. R.; Vessella, R. L. Biotin reagents for antibody pretargeting. 3. Synthesis, radioiodination, and evaluation of biotinylated starburst dendrimers, Bioconjug. Chem., 1998, 9 (6), 813-825.
85. Wilbur, D. S.; Chyan, M. K.; Pathare, P. M.; Hamlin, D. K.; Frownfelter, M. B.; Kegley, B. B. Biotin reagents for antibody pretargeting. 4. Selection of biotin conjugates for in vivo application based on their dissociation rate from avidin and streptavidin, Bioconjug. Chem., 2000, 11 (4), 569-583.
86. Wilbur, D. S.; Chyan, M. K.; Hamlin, D. K.; Vessella, R. L.; Wedge, T. J.; Hawthorne, M. F. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination, Bioconjug. Chem., 2007, 18 (4), 1226-1240.
87. Wilbur, D. S.; Chyan, M. K.; Hamlin, D. K.; Perry, M. A. Reagents for Astatination of Biomolecules. 3. Comparison of closo-Decaborate(2-) and closo-Dodecaborate(2-) Moieties as Reactive Groups for Labeling with Astatine-211, Bioconjug. Chem., 2009, 20 (3), 591-602.
88. Wilbur, D. S.; Hamlin, D. K.; Chyan, M. K.; Kegley, B. B.; Pathare, P. M. Biotin reagents for antibody pretargeting. 5. Additional studies of biotin conjugate design to provide biotinidase stability, Bioconjug. Chem., 2001, 12 (4), 616-623.
89. Wilbur, D. S.; Hamlin, D. K.; Pathare, P. M.; Weerawarna, S. A. Biotin reagents for antibody pretargeting. Synthesis, radioiodination, and in vitro evaluation of water soluble, biotinidase resistant biotin derivatives, Bioconjug. Chem., 1997, 8 (4), 572-584.
90. Wilbur, D. S.; Hamlin, D. K.; Chyan, M. K.; Kegley, B. B.; Quinn, J.; Vessella, R. L. Biotin reagents in antibody pretargeting. 6. Synthesis and in vivo evaluation of astatinated and radioiodinated aryl-and nido-carboranyl-biotin derivatives, Bioconjug. Chem., 2004, 15 (3), 601-616.
91. ed.; CRC Press: Boca Raton, 1977.
92. Lindegren, S.; Andersson, H.; Jacobsson, L.; Back, T.; Skarnemark, G.; Karlsson, B. Synthesis and biodistribution of 211At-labeled, biotinylated, and charge-modified poly-L-lysine: evaluation for use as an effector molecule in pretargeted intraperitoneal tumor therapy, Bioconjug. Chem., 2002, 13 (3), 502-509.
93. Lindegren, S.; Karlsson, B.; Jacobsson, L.; Andersson, H.; Hultborn, R.; Skarnemark, G. (211)At-labeled and biotinylated effector molecules for pretargeted radioimmunotherapy using poly-L-and poly-D-Lysine as multicarriers, Clin. Cancer Res., 2003, 9 (10 Pt 2), 3873S-3879S.
94. del Rosario, R. B.; Wahl, R. L. Biotinylated iodo-polylysine for pretargeted radiation delivery, J. Nucl. Med., 1993, 34 (7), 1147-1151.
95. Frost, S. H.; Jensen, H.; Lindegren, S. In vitro evaluation of avidin antibody pretargeting using 211At-labeled and biotinylated poly-Llysine as effector molecule, Cancer, 2010, 116 (4 Suppl), 1101-1110.
96. Atcher, R. W.; Friedman, A. M.; Hines, J. J. An improved generator for the production of 212Pb and 212Bi from 224Ra, Int J Rad Appl Instrum A, 1988, 39 (4), 283-286.
97. Su, F. M.; Beaumier, P.; Axworthy, D.; Atcher, R.; Fritzberg, A. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator, Nucl. Med. Biol., 2005, 32 (7), 741-747.
98. Mirzadeh, S.; Kumar, K.; Gansow, O. A. The Chemical Fate of Bi-212-Dota Formed by Beta-Decay of Pb-212(Dota)2-, Radiochimica Acta, 1993, 60 (1), 1-10.
99. Yao, Z.; Zhang, M.; Garmestani, K.; Axworthy, D. B.; Mallett, R. W.; Fritzberg, A. R.; Theodore, L. J.; Plascjak, P. S.; Eckelman, W. C.; Waldmann, T. A.; Pastan, I.; Paik, C. H.; Brechbiel, M. W.; Carrasquillo, J. A. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N, N', N", N"'-tetraacetic acid-biotin, Clin. Cancer Res., 2004, 10 (9), 3137-3146.
100. Zhang, M.; Yao, Z.; Garmestani, K.; Axworthy, D. B.; Zhang, Z.; Mallett, R. W.; Theodore, L. J.; Goldman, C. K.; Brechbiel, M. W.; Carrasquillo, J. A.; Waldmann, T. A. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213, Blood, 2002, 100 (1), 208-216.
101. Roselli, M.; Milenic, D. E.; Brechbiel, M. W.; Mirzadeh, S.; Pippin, C. G.; Gansow, O. A.; Colcher, D.; Schlom, J. In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts, Cancer Biother Radiopharm, 1999, 14 (3), 209-220.
102. Wilbur, D. S.; Hamlin, D. K.; Chyan, M. K.; Brechbiel, M. W. Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particleemitting radionuclides 213Bi and 211At, Bioconjug. Chem., 2008, 19 (1), 158-170.
103. Wilbur, D. S.; Chyan, M. K.; Hamlin, D. K.; Vessella, R. L.; Wedge, T. J.; Hawthorne, M. F. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination, Bioconjug. Chem., 2007, 18 (4), 1226-1240.
104. Wilbur, D. S.; Hamlin, D. K.; Buhler, K. R.; Pathare, P. M.; Vessella, R. L.; Stayton, P. S.; To, R. Streptavidin in antibody pretargeting. 2. Evaluation Of methods for decreasing localization of streptavidin to kidney while retaining its tumor binding capacity, Bioconjug. Chem., 1998, 9 (3), 322-330.
105. Aaij, C.; Tschroots, W.; Lindner, L.; Feltkamp, T. E. The preparation of astatine labelled proteins, Int J Appl Radiat Isot, 1975, 26 (1), 25-30.
106. Vaughan, A. T.; Fremlin, J. H. The preparation of astatine labelled proteins using an electrophilic reaction, Int J Nucl Med Biol, 1978, 5 (6), 229-230.
107. Lindegren, S.; Frost, S.; Back, T.; Haglund, E.; Elgqvist, J.; Jensen, H. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate, J. Nucl. Med., 2008, 49 (9), 1537-1545.
108. Visser, G. W. M.; Diemer, E. L.; Kaspersen, F. M. The Nature of the Astatine-Protein Bond, Int. J. Appl. Radiat. Isot., 1981, 32 (12), 905-912.
109. Morandeau, L.; Benoist, E.; Loussouarn, A.; Ouadi, A.; Lesaec, P.; Mougin, M.; Faivre-Chauvet, A.; Le Boterff, J.; Chatal, J. F.; Barbet, J.; Gestin, J. F. Synthesis of new bivalent peptides for applications in the Affinity Enhancement System, Bioconjug. Chem., 2005, 16 (1), 184-193.
110. Aarts, F.; Boerman, O. C.; Sharkey, R. M.; Hendriks, T.; Chang, C. H.; McBride, W. J.; Bleichrodt, R. P.; Oyen, W. J.; Goldenberg, D. M. Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab')2 antibody, Cancer, 2010, 116 (4 Suppl), 1111-1117.
111. Forero, A.; Weiden, P. L.; Vose, J. M.; Knox, S. J.; LoBuglio, A. F.; Hankins, J.; Goris, M. L.; Picozzi, V. J.; Axworthy, D. B.; Breitz, H. B.; Sims, R. B.; Ghalie, R. G.; Shen, S.; Meredith, R. F. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma, Blood, 2004, 104 (1), 227-236.
112. McDevitt, M. R.; Finn, R. D.; Ma, D.; Larson, S. M.; Scheinberg, D. A. Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use, J Nucl Med, 1999, 40 (10), 1722-1727.
113. Ruegg, C. L.; Anderson-Berg, W. T.; Brechbiel, M. W.; Mirzadeh, S.; Gansow, O. A.; Strand, M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody, Cancer Res., 1990, 50 (14), 4221-4226.